Novo Nordisk's Oral Semaglutide Shows 14% Reduction in Heart Risks

The pill form of the diabetes drug Rybelsus demonstrates significant cardiovascular benefits in a major clinical trial.

• The Phase 3 SOUL trial involved 9,650 participants with type 2 diabetes and cardiovascular or kidney disease.
• Oral semaglutide, branded as Rybelsus, was tested as an addition to standard care, cutting major adverse cardiovascular events by 14%.
• The trial's primary endpoint was a reduction in cardiovascular death, non-fatal heart attack, and stroke.
• Novo Nordisk plans to seek FDA and EU approval for Rybelsus to include heart risk reduction on its label.
• Full trial results are scheduled for presentation at a scientific conference in 2025.

4 Articles

Quartz Quartz Healio